Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
141.39 USD   +2.12%
05/27INSIDER SELL : Seagen
MT
05/26Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
CI
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Seagen

11/08/2021 | 07:20am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about SEAGEN INC.
05/27INSIDER SELL : Seagen
MT
05/26Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS® Combinatio..
CI
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
MT
05/23SEAGEN : Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (..
PU
05/23SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® ..
BU
05/23Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUK..
CI
05/23SEAGEN INC. : SEC Filing 8K
CO
05/19SEAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 793 M - -
Net income 2022 -651 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -39,9x
Yield 2022 -
Capitalization 26 026 M 26 026 M -
EV / Sales 2022 13,6x
EV / Sales 2023 9,62x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 141,39 $
Average target price 160,94 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-8.54%26 026
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
ICON PUBLIC LIMITED COMPANY-26.61%18 478
CELLTRION, INC.-21.21%17 245